CompletedPhase 3NCT00690573

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Studying Juvenile idiopathic arthritis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Abbott
Principal Investigator: Shigeki Hashimoto, PhD
Abbott Japan Co.,Ltd
Intervention: Adalimumab(biological)
Enrollment: 25 enrolled
Eligibility: 4-17 years · All sexes
Timeline: 2008 – 2011

Study locations (12)

Site Reference ID/Investigator# 47248, Aichi, Japan
Site Reference ID/Investigator# 47253, Fukuoka, Japan
Site Reference ID/Investigator# 47251, Hyōgo, Japan
Site Reference ID/Investigator# 47254, Kagoshima, Japan
Site Reference ID/Investigator# 47250, Kobe, Japan
Site Reference ID/Investigator# 47255, Okinawa, Japan
Site Reference ID/Investigator# 7153, Sendai, Japan
Site Reference ID/Investigator# 47249, Takatsuki, Japan
Site Reference ID/Investigator# 47243, Tokyo, Japan
Site Reference ID/Investigator# 47244, Tokyo, Japan
Site Reference ID/Investigator# 47245, Tokyo, Japan
Site Reference ID/Investigator# 47246, Yokohama, Japan

Collaborators

Eisai Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00690573 on ClinicalTrials.gov

Other trials for Juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

See all trials for Juvenile idiopathic arthritis →

← Back to all trials